Steven Cohen Cara Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.67 - $3.33 $11,850 - $23,629	-7,096 Reduced 98.39%	116 $0
Q2 2023 Aug 14, 2023	SELL	$2.83 - $4.94 $20,896 - $36,476	-7,384 Reduced 50.59%	7,212 $20,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $71,374 - $179,092	14,596 New	14,596 $71,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $13.84 $3.42 Million - $6.35 Million	-459,100 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $1 Million - $1.28 Million	100,800 Added 28.13%	459,100 $5.58 Million

Q4 2021 Feb 14, 2022	BUY	$11.99 - $18.14 $4.3 Million - $6.5 Million	358,300 New	358,300 $4.36 Million
Q1 2020 May 15, 2020	SELL	$9.12 - $17.78 $758,783 - $1.48 Million	-83,200 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.11 - $25.98 $1.11 Million - $1.79 Million	-68,896 Reduced 45.3%	83,200 $1.34 Million
Q3 2019 Nov 15, 2019	BUY	$18.28 - $26.91 $2.78 Million - $4.09 Million	152,096 New	152,096 $2.78 Million
Q2 2019 Aug 14, 2019	SELL	$17.68 - $21.57 $1.61 Million - $1.97 Million	-91,324 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$14.41 - $19.64 $1.32 Million - $1.79 Million	91,324 New	91,324 $1.79 Million

102

21.5M

50K

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $14M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.